Express Pharma

APRIL 8, 2025

Novo Nordisk has released full results from the SOUL cardiovascular outcomes trial, a phase 3b study evaluating the impact of oral semaglutide on adults with type 2 diabetes who also have cardiovascular disease (CVD) and/or chronic kidney disease (CKD). Notably, participants from the Asian region showed a 27 per cent reduction in MACE risk.

Diabetes 89

Diabetes Hospitals Labelling 89

Pharma Marketing Network

JUNE 15, 2025

Missteps in off-label promotion or data security can trigger legal and reputational risks. For example, oncology-focused HCPs may need different resources than those treating Type 2 diabetes. While email remains a powerful tool for engaging healthcare professionals and patients, it’s subject to unique constraints.

HIPAA 52

HIPAA Labelling Communication Diabetes 52

Pharmacy Times

JULY 17, 2025

1 Image Credit: Syahrir | stock.adobe.com Gabapentin is FDA approved for partial seizures and postherpetic neuralgia, but has widespread off-label use for various chronic pain conditions, including back pain.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunity 26

European Pharmaceutical Review

JUNE 12, 2025

Inconsistencies : data should be formatted and labelled in a well-defined way, as ambiguity would trick both humans and models. Methodology for Safe and Secure AI in Diabetes Management. Common challenges and solutions for data quality Missing data : this is an obstacle to accuracy as it omits valuable context and information.

Drug Development 52

Drug Development Documentation Labelling Diabetes 52

Pharmacy Times

JUNE 27, 2025

Although no formal contraindications are listed in AstraZeneca’s US labeling, perioperative management may require holding acalabrutinib 3 to 7 days before and after surgery to minimize bleeding risk. Hepatotoxicity and drug-induced liver injury are additional risks that require monitoring.

Pharmacy Technician 22

Pharmacy Technician Diabetes Compounding Pharmacies Pharmacy Management 22

Pharma Marketing Network

JULY 7, 2025

For example, a diabetes drug brand may run display ads while simultaneously sending educational emails. Ads must include proper disclosures, balance benefit-risk information, and avoid off-label promotion. Yet, when done correctly, PPC remains one of the few digital strategies that delivers immediate visibility and trackable ROI.

Labelling 52

Labelling Diabetes 52

Pharma Marketing Network

JULY 14, 2025

Furthermore, branded drugs must now navigate digital labeling, AI-assisted prescribing tools, and cross-border telehealth platforms. Maintaining consistency in a brand’s core message while customizing for local legal and cultural nuances is no small feat. More importantly, pharmaceutical branding must now prioritize both reach and resonance.

Biosimilars 52

Biosimilars HIPAA Labelling Diabetes 52

Pharmacy Times

JUNE 16, 2025

The findings emphasize nemolizumab’s swift response in treating atopic dermatitis symptoms, along with its long-term effectiveness in prurigo nodularis, as demonstrated in the OLYMPIA open-label extension trial (NCT04204616).

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 26

Pharmacy Times

JUNE 30, 2025

Accurate product labeling and ongoing safety monitoring remain essential for patient safety in CAR T therapies. Still, providing accurate product labeling for these products—which properly conveys the risks of CRS and neurological toxicities—remains essential to ensuring patient safety.

Pharmacy Technician 40

Pharmacy Technician Compounding Pharmacies Immunity Immunization 40

Pharmacy Times

JUNE 23, 2025

Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. In the 505(j) ANDA approval pathway, on the other hand, submissions can be multisource generic drugs; however, this pathway requires bioequivalence to the RLD.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

Pharmacy Times

JULY 10, 2025

If approved, lumatperone’s expanded label could offer health care teams a valuable tool to improve stability, well-being, and real-world outcomes for patients with schizophrenia. 1-3 REFERENCES 1. Johnson & Johnson.

Pharmacy Technician 20

Pharmacy Technician Hospitals Compounding Pharmacies Pharmacy Management 20

Pharmacy Times

JULY 1, 2025

Additionally, tafamidis stands out compared with other TTR stabilizers that are used off-label and require monitoring for renal and gastrointestinal AEs. In addition to efficacy and safety, the investigators aim to provide valuable information on functional capacity and survival in this open-label extension.

HIV Treatment and Prevention Agents 44

HIV Treatment and Prevention Agents Pharmacy Technician Insurance Coverage and Processing Specialty Pharmacies 44

Pharmacy Times

JULY 15, 2025

months progression-free survival in real-world RRMM patients, consistent with KarMMa trial results.

Pharmacy Technician 29

Pharmacy Technician Immunity Immunization Compounding Pharmacies 29

Pharmacy Times

JULY 14, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Independent Pharmacies 51

Independent Pharmacies Pharmacy Technician Compounding Pharmacies Hospitals 51

Pharmacy Times

JULY 7, 2025

Risk factors that could increase the development of HCC, along with chronic liver conditions, include older age, excess fat in the liver, diabetes, obesity, exposure to aflatoxins, excessive alcohol consumption, and cigarette smoking. 2 "The expanded indication makes SIR-Spheres ® the only Y-90 treatment approved in the U.S.

Pharmacy Technician 20

Pharmacy Technician Compounding Pharmacies Diabetes Pharmacy Management 20

Pharmacy Times

JUNE 16, 2025

1 As part of another action designed to reduce drug costs, Newsom also announced the expansion of CalRx, the state’s initiative to produce generic drugs under the state’s own label, giving CalRx the authority to purchase brand-name drugs. Furthermore, DMHC would have clear authority to enforce rules and penalize violations.

Pharmacy Technician 26

Pharmacy Technician Drug Pricing Insurance Coverage and Processing Compounding Pharmacies 26

Pharmacy Times

JUNE 20, 2025

There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. Oncology pharmacy practice changes at a rapid pace. Fifteen years ago, pharmacists could learn oncology on the job.

Pharmacy Technician 46

Pharmacy Technician Compounding Compounding Pharmacies Biosimilars 46

Pharmacy Times

JULY 2, 2025

2,4 The open-label, single-arm, multicenter, multidose study enrolled 86 patients with CKD and hyperphosphatemia receiving maintenance hemodialysis. The trial’s primary objective was to evaluate the tolerability of OLC at its clinically effective doses (goal: serum phosphate ≤ 5.5

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Pharmacy Management Adverse Reactions 29

Pharmacy Times

JULY 15, 2025

Just to share a little bit more about our medication packets: these packets are labeled by date and time, and they come in a monthly pill dispenser box. Those packets come right out of the box, and you're able to tear them away.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Pharmacies Biosimilars 26

Pharmacy Times

JULY 10, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician 26

Pharmacy Technician Immunity Immunization Specialty Pharmacies 26

Pharmacy Times

JUNE 9, 2025

These conclusions were presented as part of an abstract from the open-label, phase 3 CheckMate 816 trial (NCT02998528) at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, and subsequently published in the Journal of Clinical Oncology.

Chemotherapy 26

Chemotherapy Pharmacy Technician Immunity Immunization 26

Pharmacy Times

JULY 7, 2025

Limitations included open-label design and dosage constraints, but the multicountry approach enhanced generalizability and external validity. The phase 3 trial demonstrated comparable safety profiles between efepoetin alfa and Mircera, with a slightly higher response rate for efepoetin alfa.

Pharmacy Technician 39

Pharmacy Technician Compounding Pharmacies Dosage Diabetes 39

Pharmacy Times

JUNE 5, 2025

Detect-A-Dose lid-label cover enhances medication recognition, reducing packaging errors through a contrasting visual pattern. 1-3 Detect-A-Dose Lid Label Covers. 4 Detect-A-Dose features a contrasting black and white pattern on the underside of its label to make missing doses for patients apparent to pharmacists.

Pharmacy Technician 26

Pharmacy Technician Packaging Labelling Immunity 26

Pharmacy Times

JUNE 23, 2025

It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans. The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target.

Diabetes 32

Diabetes HIV Treatment and Prevention Agents Pharmacy Technician Compounding Pharmacies 32

Pharma Marketing Network

MARCH 8, 2025

diabetes, cancer). No unapproved drug claims All claims must be backed by clinical research and FDA-approved labeling. No targeting based on sensitive medical conditions (e.g., Landing pages must align with ad content misleading claims can lead to account suspension.

HIPAA 59

HIPAA Pharmaceutical Companies Pharmaceutical Companies Labelling 59

Putting Patients First Blog

JUNE 26, 2025

This step would ensure that real-world considerations, such as off-label uses and quality-of-life impacts, are factored into revised pricing decisions. A minimum 60-day window for public input should be established, with outreach to affected patient groups.

Drug Pricing 52

Drug Pricing Communication Drug Development Documentation 52

Pharmacy Times

JUNE 23, 2025

Along with the successful pivotal trials, Launch-HTN and Advance-HTN, and the ongoing open-label extension trial, these results comprise the core package for our planned NDA submission.” Explore-CKD established that lorundrostat 25 mg once daily has a favorable clinical profile for this patient population.

Pharmacy Technician 51

Pharmacy Technician Diabetes Compounding Pharmacies Pharmacy Management 51

Pharmacy Times

JUNE 30, 2025

2-5 In the multicenter, phase 2, open-label prospective study, researchers investigated ropeg-IFN-α2b treatment in patients with profibrotic MF or DIPSS low-intermediate-1 risk MF. With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi. Updated November 30, 2023. Accessed June 30, 2025.

Pharmacy Technician 34

Pharmacy Technician Compounding Pharmacies Pharmacy Management Diabetes 34

Pharmacy Times

JULY 3, 2025

Typically, it's a white-labeled experience, so it has the look and feel of that digital therapeutic throughout the entire experience. What we do is create a very nice UI/UX digital experience so we can onboard patients, receive payment, and then hand them off to the digital therapeutic.

Pharmacy Technician 32

Pharmacy Technician Compounding Pharmacies Pharmacy Management Diabetes 32

Pharmacy Times

JUNE 11, 2025

Its efficacy was evaluated in the 2 multicenter, single-arm open-label phase 2 clinical trials TRUST-I (NCT04395677) 3 and TRUST-II (NCT04919811). Taletrectinib is an oral, potent, central nervous system (CNS)–active, selective, next generation ROS1 inhibitor approved for the treatment of adults with advanced ROS1+ NSCLC.

Pharmacy Technician 29

Pharmacy Technician Biosimilars Compounding Pharmacies Pharmacy Management 29

Pharmacy Times

JUNE 9, 2025

2 However, Dalton noted that some procedures can change once a treatment is FDA-approved, with complications from Risk Evaluation and Mitigation Strategy programs as well as the occasional surprise on an FDA label. But doing so requires a new kind of expertise that spans science, strategy, and systems thinking.

Pharmacy Technician 22

Pharmacy Technician Compounding Pharmacies Pharmacy Management Hospitals 22

Pharmacy Times

JUNE 12, 2025

Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: A single-arm, open-label, phase 3 trial (ENVISION). Prasad SM, Shishkov D, Mihaylov NV, et al. February 1, 2025. doi:10.1097/JU.0000000000004296 0000000000004296 4.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 26

Pharmacy Times

JULY 9, 2025

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). million individuals in the United States aged 65 and older.

Labelling 26

Labelling Pharmacy Technician Independent Pharmacies Compounding Pharmacies 26

Pharmacy Times

JUNE 9, 2025

3 neoCARHP was a multicenter, open-label, randomized, noninferiority phase 3 trial (NCT04858529) that compared the efficacy and safety of TCbHP with THP in the neoadjuvant setting. If caught early, the cancer can often be treated and cured, according to Cleveland Clinic. Gao HF, Li W, Wu Z, et al. J Clin Oncol. doi:10.1200/JCO.2025.43.17_suppl.LBA500

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management 26

Pharma Marketing Network

JUNE 23, 2025

Ad creatives must be approved by legal and medical review teams to meet FDA labeling requirements. For example, a diabetes drug campaign may target endocrinologists during clinical journal reading sessions or serve banners to patients browsing content about managing A1C levels.

HIPAA 52

HIPAA Labelling Diabetes 52

PharmaTech

JULY 4, 2025

While treatments for infection, inflammation, high eye pressure, and neovascularization have been shown to be effective, this method of delivery is considered “off-label,” as FDA has not approved products specifically for this use, except two intracameral implants (see below). In addition, many patients are hesitant to receive eye injections.

Dosage 64

Dosage Drug Development Vaccines Diabetes 64

Pharmacy Times

JUNE 30, 2025

2,3 LIMBER is a phase 1, open-label, dose escalation study evaluating INCB057643 as a monotherapy at a dose escalation of 4 to 12 mg daily (part 1) or in combination with ruxolitinib at a dosage of 4 mg once daily and escalating to the maximum tolerated dose in part 1 (part 2).

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management 26